中文摘要：

目的建立人卵巢癌紫杉醇耐药细胞株（Skov-3/PTX）,并对其生物学性状进行检测和鉴定。方法采用紫杉醇浓度梯度递增法,建立人卵巢癌紫杉醇耐药株。通过细胞形态学观察、生长曲线和群体倍增时间测定、药物敏感试验、细胞内Rh-123和紫杉醇含量研究及MDR1、MRP和GST-πmRNA水平的测定,评价Skov-3/PTX生物学特性。结果成功建立了Skov-3/PTX耐药株,耐药指数为45.90,对吉非替尼、9-硝基喜树碱和阿霉素产生明显的交叉耐药性。与Skov-3细胞相比,Skov-3/PTX耐药细胞异形明显;耐药细胞倍增时间显著延长（P〈0.05）;耐药细胞内Rh-123和紫杉醇量显著减少（P〈0.05）,环孢菌素可以增加细胞内Rh-123和紫杉醇含量;耐药细胞的MDR1、MRP和GST-πmRNA水平显著增高。结论Skov-3/PTX细胞具有典型多药耐药特性,为进一步研究耐药逆转途径提供了实验基础。

英文摘要：

Objective To establish paclitaxel-resistant cell line of human ovarian cancer（Skov-3/PTX）and to investigate its biological features.Methods Paclitaxel-resistant cell line of human ovarian cancer（Skov-3/PTX）was established by continuous stepwise selection in increasing concentration of paclitaxel.Cell morphology,growth curve and population doubling time,cell uptake of Rh-123 and paclitaxel,mRNA level of MDR1,MRP and GST-π were investigated to determine the biological features of Skov-3/PTX cell line.Results The resistance index（RI）of Skov-3/PTX cells was up to 45.90.They showed an obvious cross-resistance to gefitinib,9-nitrocamptothecin and adriamycin.The results of uptake of Rh-123 and PTX further proved that Skov-3/PTX cells had significant resistance to Rh-123 and PTX,and P-glycoprotein substrate,CsA could increase the uptake of drug in resistant cells.PT-PCR studies showed that the levels of MDR1,MRP and GST-π mRNA expression in the Skov-3/PTX cells were higher than the sensitive cells.Conclusions Skov-3/PTX cell line shows typical multidrug resistance phenotypes and might serve as an ideal model for exploring the new route of reversing multidrug resistance.